Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in slovenia : a cohort study
Avtorji:ID Rotar, Žiga (Avtor)
ID Svetina, Petra, Klinika Golnik (Avtor)
ID Tomšič, Matija (Avtor)
ID Hočevar, Alojzija (Avtor)
ID Praprotnik, Sonja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (445,46 KB)
MD5: DAD0E176B5D746D576E7AE6AC2677BC7
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Objectives: This study aimed to assess the risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treated with any of the commercially available tumour necrosis factor inhibitors (TNFis) in Slovenia. Design: This is a cohort, registry (biorx.si) cross-linked with the Slovenian National TB Registry. Setting: National, involving all Slovenian rheumatology centres (six secondary and two secondary/tertiary). Participants: 2429 patients with RA, AS or PsA exposed to at least one TNFi participated in the study. Primary and secondary outcome measures: The primary outcome measures were age-adjusted and sex-adjusted TB incidence rates (IRs) and the standardised incidence ratios (SIRs) compared with the general population exploring different TNFi exposure windows. The secondary outcome measures were a detailed characterisation of the national latent tuberculosis infection (LTBI) screening and TB chemoprophylaxis protocol implementation. Results: Among the 2429 patients exposed to at least one TNFi for a total of 10 445 (49% RA, 33% AS and 18% PsA) person-years (PY), 99% completed LTBI screening and 6% required TB chemoprophylaxis. Six RA (three adalimumab, three certolizumab), two PsA (two golimumab) and zero AS patients developed TB. Five out of eight had miliary TB, three out of eight had pulmonary TB and two patients died. The age-standardised and sex-standardised TB IR (95% CI) per 100 000 PYs/SIRs (95% CI) compared with the general Slovenian population for the current TNFi exposure were 52 (0 to 110)/6.7 (0.6 to 80), 47 (0 to 110)/6.1 (0.3 to 105), 45 (0 to 109)/5.8 (0.3 to 112) overall, in RA and PsA, respectively. Conclusions: The TB IR in the Slovenian patients with RA, AS and PsA treated with TNFi was comparable with TB IRs in TB non-endemic countries with less than a tenth of the patients requiring TB chemoprophylaxis.
Ključne besede:epidemiology, rheumatology, tuberculosis
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Velika Britanija
Založnik:BMJ Publishing
Leto izida:2020
Št. strani:str. 1-11
Številčenje:Vol. 10, iss. 2
PID:20.500.12556/DiRROS-12624 Novo okno
UDK:616.2
ISSN pri članku:2044-6055
DOI:10.1136/bmjopen-2019-034356 Novo okno
COBISS.SI-ID:17828099 Novo okno
Avtorske pravice:© Author(s) (or their employer(s)) 2020
Opomba:Soavtorji: Petra Svetina, Matija Tomsic, Alojzija Hočevar, Sonja Prapotnik; Nasl. z nasl. zaslona; Opis vira z dne 3. 6. 2020;
Datum objave v DiRROS:12.11.2020
Število ogledov:1689
Število prenosov:737
Metapodatki:XML DC-XML DC-RDF
:
ROTAR, Žiga, SVETINA, Petra, TOMŠIČ, Matija, HOČEVAR, Alojzija in PRAPROTNIK, Sonja, 2020, Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in slovenia : a cohort study. BMJ open [na spletu]. 2020. Vol. 10, no. 2, p. 1–11. [Dostopano 6 april 2025]. DOI 10.1136/bmjopen-2019-034356. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=12624
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:BMJ open
Založnik:BMJ Publishing
ISSN:2044-6055
COBISS.SI-ID:30480601 Novo okno

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Začetek licenciranja:21.01.2020

Sekundarni jezik

Jezik:Ni določen
Ključne besede:epidemiologija, revmatologija, tuberkuloza


Nazaj